Emcure Pharmaceuticals Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

CMP Rs 1790.3. FY26 EPS Rs 48.8; 15% annual growth. Target 2027: Rs 1,795 (+0%). Target 2028: Rs 2,060. Target 2030: Rs 2,730 (+52%).

Emcure Pharmaceuticals at Rs 1,790.3 is a company with a familiar face: Executive Director Namita Thapar appears regularly on Shark Tank India, giving Emcure retail brand recognition that most pharma companies lack. But the Emcure Pharmaceuticals share price target of Rs 1,795 for 2027, rising to Rs 2,730 by 2030, rests on a different foundation: a complex generics and specialty pharma portfolio spanning gynaecology, oncology, and cardiovascular therapy with significant Europe and North America revenue.

The Emcure Pharmaceuticals share price target of Rs 1,795 for 2027, rising to Rs 2,730 by 2030, reflects 15% annual earnings growth with a forward multiple consistent with Pharma peers. This article covers the Emcure Pharmaceuticals share price target 2027, 2028, and 2030 based on FY26 financials and analyst estimates as of August 2026.

Click Here – Get Free Investment Predictions

Emcure Pharmaceuticals Company Overview

Metric	Details
NSE Ticker	EMCURE
Sector	Pharma
CMP (07 Aug 2026)	Rs 1790.3
52-Week High	Rs 2,100
52-Week Low	Rs 1,250
Market Cap	Rs 34,448 Cr
FY26 EPS	Rs 48.8 (15% annual growth)
Promoter Holding	57%
12M Consensus	₹1,720 (-4%)
Emcure Pharmaceuticals Share Price Target 2027	Rs 1,795 (+0%)
Emcure Pharmaceuticals Share Price Target 2028	Rs 2,060 (+15%)
Emcure Pharmaceuticals Share Price Target 2030	Rs 2,730 (+52%)
Bull Case 2030	Rs 3,494
Bear Case 2030	Rs 2,075

What most investors miss: Bain Capital was a pre-IPO PE backer of Emcure, retaining a residual post-IPO stake that is a potential supply overhang. Executive Director Namita Thapar, of Shark Tank India fame, is a promoter shareholder whose public visibility is the brand, not the business model. The stock’s 2027 target of Rs 1,795 essentially represents flat earnings-to-valuation, with the compounding case playing out from 2028 to 2030 as the specialty pharma pipeline matures.

FY26 EPS of ₹48. 8 growing approximately15% a year, capitalised at approximately32x forward earnings; growth tapers to approximately12% further out. The share price targets of Rs 1,795 for 2027, Rs 2,060 for 2028, and Rs 2,730 for 2030 are derived from this earnings trajectory and peer multiples.

Why Is the Emcure Pharmaceuticals Share Price Target Set at Rs 1,795 for 2027

Complex Generics in Gynaecology and Oncology Drive International Revenue

This is the foundational driver of the Emcure Pharmaceuticals share price target of Rs 1,795 for 2027 and Rs 2,730 by 2030. FY26 EPS of ₹48.8 growing approximately15% a year, capitalised at approximately32x forward earnings; growth tapers to approximately12% further out. Street consensus (1-yr) sits at ₹1,720. The market will progressively price this as quarterly data confirms the trajectory.

Specialty Pharma Pipeline Provides Earnings Upside Beyond Base Formulations

Investors analysing the Emcure Pharmaceuticals share price target should track this dimension quarterly, as it provides the clearest signal of whether the compounding thesis is on track. Evidence of sustained improvement in this area is the primary re-rating catalyst for the Emcure Pharmaceuticals share price target 2028 of Rs 1969.

Bain Capital Residual Stake Is a Known and Declining Supply Overhang

This structural factor is often underweighted in standard Emcure Pharmaceuticals share price target analyses, which focus on trailing earnings multiples rather than the competitive positioning embedded in the long-term franchise value. Its persistence through economic cycles is what differentiates the Emcure Pharmaceuticals share price target 2030 case from a short-term trading call.

European and North American Expansion Is the Long-Term Earnings Driver

For the Emcure Pharmaceuticals share price target of Rs 2,730 to materialise by 2030, this factor needs to remain intact and compound over 4 years. Quarterly updates on this metric provide the earliest warning signal of any deviation from the Emcure Pharmaceuticals share price target base case assumptions.

Domestic Branded Generics Brand Recognition Supported by Promoter Visibility

As India’s economy compounds through 2027 to 2030, this factor provides an additional secular tailwind that is layered on top of the Emcure Pharmaceuticals-specific earnings growth already embedded in the Rs 1,795 target for 2027 and the Rs 2,730 target for 2030.

Emcure Pharmaceuticals Share Price Targets 2027, 2028 and 2030

Emcure Pharmaceuticals Share Price Target 2027: Rs 1,795

The Emcure Pharmaceuticals share price target 2027 is Rs 1,795, representing approximately 0 percent upside from CMP Rs 1790.3. FY26 EPS of ₹48.8 growing approximately15% a year, capitalised at approximately32x forward earnings; growth tapers to approximately12% further out. Street consensus (1-yr) sits at ₹1,720.. By 2027, the key catalyst for achieving this level is validation of the earnings trajectory through 2 consecutive quarters of on-target performance.

Emcure Pharmaceuticals Share Price Target 2028: Rs 2,060

The Emcure Pharmaceuticals share price target 2028 is Rs 2,060, implying approximately 15 percent upside from CMP. By 2028, Emcure Pharmaceuticals should have demonstrated through a full earnings cycle that the 15% growth assumption is sustainable, supporting a re-rating toward the Emcure Pharmaceuticals share price target 2028 level at a forward multiple consistent with sector peers.

Emcure Pharmaceuticals Share Price Target 2030: Rs 2,730

The Emcure Pharmaceuticals share price target 2030 is Rs 2,730, implying approximately 52 percent upside from CMP and a 4-year CAGR of approximately 11% from current levels. By 2030, Emcure Pharmaceuticals should be a mature, well-understood franchise with a track record of consistent compounding that justifies the target multiple.

Bull Case and Bear Case for the Emcure Pharmaceuticals Share Price Target 2030

Bull Case: Rs 3,494

The bull case Emcure Pharmaceuticals share price target of Rs 3,494 by 2030: Rs 3,400 by 2030, requiring 18 percent EPS growth driven by successful launches in the US specialty market and Europe branded generics. Namita Thapar’s public profile accelerating domestic OTC product launches would add incremental revenue above the base case.

Bear Case: Rs 2,075

The bear case Emcure Pharmaceuticals share price target of Rs 2,075 by 2030: Rs 2,100 by 2030, if the US specialty market approvals take longer than expected, Bain Capital’s residual stake continues to weigh on sentiment, and domestic branded generics face pricing pressure from generic substitution policies.

Scenario	Target by 2030	Return	Key Assumption
Bull Case	Rs 3,494	+95%	Upside scenario with favourable execution and sector conditions
Base Case	Rs 2,730	+52%	15% EPS CAGR; peer-multiple sustained through FY31
Bear Case	Rs 2,075	+16%	Downside scenario with adverse execution or macro headwinds

Key Risks to the Emcure Pharmaceuticals Share Price Target

USFDA Inspection and Compliance Risk

Any USFDA warning letter or import alert on Emcure Pharmaceuticals’s manufacturing facilities would delay product launches and revenue recognition, directly reducing the earnings trajectory behind the Emcure Pharmaceuticals share price target. USFDA inspection history is the most important risk indicator to track.

Currency Risk on Export Revenue

Emcure Pharmaceuticals’s international revenue is primarily in US dollars and euros. Any significant INR appreciation against these currencies would reduce the INR value of reported revenues and EPS, compressing the Emcure Pharmaceuticals share price target earnings assumptions.

Pricing Pressure in Regulated Generic Markets

In the US and EU generic markets, pricing erosion from competition intensifies as multiple players receive approvals for the same molecule. Any acceleration in generic pricing erosion in Emcure Pharmaceuticals’s key export products would compress the Emcure Pharmaceuticals share price target revenue base.

Clinical Trial and Pipeline Risk

Any setback in Emcure Pharmaceuticals’s clinical trial results or regulatory approvals for pipeline products would delay the revenue ramp from specialty or novel products embedded in the Emcure Pharmaceuticals share price target 2028 and 2030 assumptions.

How to Invest in Emcure Pharmaceuticals

Use the Univest Screener to track Emcure Pharmaceuticals’s key financial metrics including EPS growth, margin trends, and analyst upgrades or downgrades in real time. To purchase shares, open a demat account with any SEBI-registered broker and search for NSE ticker EMCURE. Review the quarterly earnings data, the sector-specific risk indicators outlined in this article, and build a position size proportionate to your risk tolerance and investment horizon. Monitor each quarter for the key variables most likely to move the Emcure Pharmaceuticals share price target. Consult a SEBI-registered financial advisor before making any investment decision.

Use the Univest Screener to Track This Stock Live

Conclusion

The Emcure Pharmaceuticals share price target of Rs 1,795 for 2027, Rs 2,060 for 2028, and Rs 2,730 for 2030 reflects 15% annual earnings compounding and a forward multiple consistent with Pharma peers. The key drivers and risks are outlined above. Bain Capital was a pre-IPO PE backer of Emcure, retaining a residual post-IPO stake that is a potential supply overhang. Executive Director Namita Tha. For investors with a 3 to 4 year horizon and a tolerance for Pharma-specific risk, the current CMP of Rs 1790.3 offers a starting point for building a position aligned to the Emcure Pharmaceuticals share price target 2030 thesis. Always verify data at NSE and BSE before investing.

Download the Univest iOS App or Univest Android App to track Emcure Pharmaceuticals share price live and get daily stock recommendations.

Frequently Asked Questions on Emcure Pharmaceuticals Share Price Target 2027 2028 and 2030

What is the Emcure Pharmaceuticals share price target for 2027?

Ans. The Emcure Pharmaceuticals share price target for 2027 is Rs 1,795, representing approximately 0 percent upside from CMP Rs 1790.3 as of August 2026. Please verify all data with the official NSE website before making any investment decision.

What is the Emcure Pharmaceuticals share price target for 2030?

Ans. The Emcure Pharmaceuticals share price target for 2030 is Rs 2,730, implying approximately 52 percent upside from CMP Rs 1790.3. This is based on analyst estimates and is not a guaranteed return. Always verify current data at NSE India before investing.

Is Emcure Pharmaceuticals a good long-term investment?

Ans. Emcure Pharmaceuticals has a defined analyst consensus that projects earnings compounding through FY31 based on sector-specific growth drivers outlined in this article. Whether it suits your portfolio depends on your risk appetite, investment horizon, and existing allocation. Consult a SEBI-registered financial advisor for personalised guidance.

What do most investors miss about Emcure Pharmaceuticals?

Ans. Bain Capital was a pre-IPO PE backer (invested 2013) and retains a residual post-IPO stake creating a potential supply overhang; Executive Director Namita Thapar (Shark Tank India judge) is promoter Satish Mehta’s daughter, i.e. concentrated family management. Strong hidden franchise in HIV antiretr

What is the bull case for the Emcure Pharmaceuticals share price target 2030?

Ans. The bull case Emcure Pharmaceuticals share price target for 2030 is Rs 3,494. This requires better-than-base-case execution on the key growth drivers specific to Emcure Pharmaceuticals’s sector, as described in this article. These are analyst projections, not guaranteed returns.

What are the main risks to the Emcure Pharmaceuticals share price target?

Ans. The key risks to the Emcure Pharmaceuticals share price target include sector-specific headwinds such as credit cycles (for financial companies), regulatory changes, competitive pressure, and macroeconomic slowdown. Please review the risks section of this article for a full breakdown of the four most material risks.

What is Emcure Pharmaceuticals’s 52-week high and low share price?

Ans. As of August 2026, Emcure Pharmaceuticals’s 52-week high is approximately Rs 2,100 and the 52-week low is approximately Rs 1,250. The CMP of Rs 1790.3 sits between these levels. Always verify the latest 52-week data at NSE India or BSE before making any investment decision.

How can I buy Emcure Pharmaceuticals shares?

Ans. You can buy Emcure Pharmaceuticals shares through any SEBI-registered broker by searching for the NSE ticker EMCURE. Before investing, review the fundamentals outlined in this article and consult a SEBI-registered financial advisor for guidance aligned to your specific financial goals.